Chieko Shiragami

Ikenobe, 7610793, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Increased macular atrophy area with photodynamic therapy over intravitreal aflibercept at 2-year follow-up of pachychoroid neovasculopathy.

Increased macular atrophy area with photodynamic therapy over intravitreal aflibercept at 2-year follow-up of pachychoroid neovasculopathy.

Journal: Japanese journal of ophthalmology

Published: August 09, 2024

Estimating ranibizumab injection numbers and visual acuity at 12 months based on 2-month data on branch retinal vein occlusion treatment.

Estimating ranibizumab injection numbers and visual acuity at 12 months based on 2-month data on branch retinal vein occlusion treatment.

Journal: Scientific reports

Published: November 10, 2021

Author Correction: The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment‑naïve patients.

Author Correction: The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment‑naïve patients.

Journal: Scientific reports

Published: July 08, 2021

Correlations among age, sex, axial length, and subfoveal choroidal thickness in the choriocapillaris structure analyzed using multiple en face image averaging optical coherence tomography angiography.

Correlations among age, sex, axial length, and subfoveal choroidal thickness in the choriocapillaris structure analyzed using multiple en face image averaging optical coherence tomography angiography.

Journal: PloS one

Published: April 23, 2021

Reply.

Reply.

Journal: Retina (Philadelphia, Pa.)

Published: August 26, 2020

The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients.

The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients.

Journal: Scientific reports

Published: August 07, 2020

Genome-wide association analyses identify two susceptibility loci for pachychoroid disease central serous chorioretinopathy.

Genome-wide association analyses identify two susceptibility loci for pachychoroid disease central serous chorioretinopathy.

Journal: Communications biology

Published: June 19, 2019

One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis.

One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis.

Journal: Medicine

Published: August 05, 2018

Reply.

Reply.

Journal: American journal of ophthalmology

Published: July 27, 2018

Retinal oximetry in branch retinal vein occlusion.

Retinal oximetry in branch retinal vein occlusion.

Journal: Acta ophthalmologica

Published: July 20, 2018

CFH and VIPR2 as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy.

CFH and VIPR2 as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: May 31, 2018

Clinical Features of Central Serous Chorioretinopathy With Type 1 Choroidal Neovascularization.

Clinical Features of Central Serous Chorioretinopathy With Type 1 Choroidal Neovascularization.

Journal: American journal of ophthalmology

Published: February 12, 2018

Showing 1-12 of 33

Last Updated: 09/26/2026